Learning Hub Central

2026 SPS Puerto Rico | Specialty Pharmaceuticals: The Payer Perspective

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Puerto Rico | Building Cell and Gene Therapy Program to Close Equity Gaps

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Puerto Rico | Taletrectinib Pushing Boundaries in ROS1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Puerto Rico | Telisotuzumab in the Management of Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Puerto Rico | GLP-1 Updates with Focus on Medicare Bridge Program Effective July 2026

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Puerto Rico | Caplacizumab in the Immune-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Setting. A Real-World Evidence Review of CAPLA 1000+ and MAYARI Trial

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Puerto Rico | Update on First and Only CAR-T Therapy Program in Puerto Rico

0.00 Credits

1 Chapter

Pharmacology

Free

$2026 SPS Puerto Rico | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma. A Review of Phase III IRAKLIA Study$

2026 SPS Puerto Rico | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma. A Review of Phase III IRAKLIA Study

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Two Paths, One Goal: Harnessing Bispecifics and CAR-Ts Against Hematologic Malignancies

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Hepatic Artery Infusion (HAI) Chemotherapy

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Clinical Updates and Real-World Application

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | HELIOS B Clinical Trial: Vutrisiran in the Management of Transthyretin-Mediated Amyloidosis Cardiomyopathy Patients

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Sequencing Antibody-Drug Conjugate (ADC) Therapies in Metastatic Breast Cancer

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | A Glimpse into Evolving Therapies in Non-Muscle Invasive Bladder Cancer (NMIBC)

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Pharmacist-led Implementation of Injection Administration for HIV Pre-Exposure Prophylaxis (PrEP)

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | 505(b)(2): From Opportunity Assessment to Implementation Best Practices

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Clinical and Practice Considerations for the Use of Tumor-Infiltrating Lymphocytes (TILs) in Melanoma

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Tarlatamab and Tebentafusp Bispecifics: Clinical and Practical Considerations in the Solid Tumors Setting

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Guselkumab: Place in Therapy and Clinical Considerations

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Preemptive Pharmacogenomic Testing in Patients with GI Cancers

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Role of Pharmacists in Precision Medicine

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Colorado Legislative Update

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Role of Trilaciclib as Supportive Care in the Management of Small Cell Lung Cancer (SCLC)

0.00 Credits

1 Chapter

Pharmacology

Free

2026 SPS Denver | Pharmacy Practice Model: Integration of Pharmacists in Clinics to Drive Patient Care Optimization

0.00 Credits

1 Chapter

Pharmacology

Free

$2026 SPS Denver | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma - A Review of Phase III IRAKLIA Study$

2026 SPS Denver | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma - A Review of Phase III IRAKLIA Study

0.00 Credits

1 Chapter

Pharmacology

Free

Contact Us

Learning Hub Central

Pharmacology

2026 SPS Puerto Rico | Specialty Pharmaceuticals: The Payer Perspective

2026 SPS Puerto Rico | Building Cell and Gene Therapy Program to Close Equity Gaps

2026 SPS Puerto Rico | Taletrectinib Pushing Boundaries in ROS1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

2026 SPS Puerto Rico | Telisotuzumab in the Management of Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

2026 SPS Puerto Rico | GLP-1 Updates with Focus on Medicare Bridge Program Effective July 2026

2026 SPS Puerto Rico | Caplacizumab in the Immune-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Setting. A Real-World Evidence Review of CAPLA 1000+ and MAYARI Trial

2026 SPS Puerto Rico | Update on First and Only CAR-T Therapy Program in Puerto Rico

2026 SPS Puerto Rico | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma. A Review of Phase III IRAKLIA Study

2026 SPS Denver | Two Paths, One Goal: Harnessing Bispecifics and CAR-Ts Against Hematologic Malignancies

2026 SPS Denver | Hepatic Artery Infusion (HAI) Chemotherapy

2026 SPS Denver | Clinical Updates and Real-World Application

2026 SPS Denver | HELIOS B Clinical Trial: Vutrisiran in the Management of Transthyretin-Mediated Amyloidosis Cardiomyopathy Patients

2026 SPS Denver | Sequencing Antibody-Drug Conjugate (ADC) Therapies in Metastatic Breast Cancer

2026 SPS Denver | A Glimpse into Evolving Therapies in Non-Muscle Invasive Bladder Cancer (NMIBC)

2026 SPS Denver | Pharmacist-led Implementation of Injection Administration for HIV Pre-Exposure Prophylaxis (PrEP)

2026 SPS Denver | 505(b)(2): From Opportunity Assessment to Implementation Best Practices

2026 SPS Denver | Clinical and Practice Considerations for the Use of Tumor-Infiltrating Lymphocytes (TILs) in Melanoma

2026 SPS Denver | Tarlatamab and Tebentafusp Bispecifics: Clinical and Practical Considerations in the Solid Tumors Setting

2026 SPS Denver | Guselkumab: Place in Therapy and Clinical Considerations

2026 SPS Denver | Preemptive Pharmacogenomic Testing in Patients with GI Cancers

2026 SPS Denver | Role of Pharmacists in Precision Medicine

2026 SPS Denver | Colorado Legislative Update

2026 SPS Denver | Role of Trilaciclib as Supportive Care in the Management of Small Cell Lung Cancer (SCLC)

2026 SPS Denver | Pharmacy Practice Model: Integration of Pharmacists in Clinics to Drive Patient Care Optimization

2026 SPS Denver | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma - A Review of Phase III IRAKLIA Study

Contact Us